ATE192737T1 - Aralkoxy und aralkylthio substituierte azacyclische verbindungen als tachykinin antagonisten - Google Patents

Aralkoxy und aralkylthio substituierte azacyclische verbindungen als tachykinin antagonisten

Info

Publication number: ATE192737T1
Authority: AT; Austria
Prior art keywords: 6alkyl; optionally substituted; substituted; nrarb; pct
Prior art date: 1994-02-11

Application number

AT95907110T

Other languages

English (en)

Inventor

Raymond Baker

Angus Murray Macleod

Eileen Mary Seward

Christopher John Swain

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-02-11

Filing date

1995-02-06

Publication date

2000-05-15

1995-02-06 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2000-05-15 Application granted granted Critical

2000-05-15 Publication of ATE192737T1 publication Critical patent/ATE192737T1/de

Links

102000003141 Tachykinin Human genes 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
150000004030 azacyclic compounds Chemical class 0.000 title 1
108060008037 tachykinin Proteins 0.000 title 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
229910003827 NRaRb Inorganic materials 0.000 abstract 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
241000689227 Cora <basidiomycete fungus> Species 0.000 abstract 2
125000003118 aryl group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
125000001475 halogen functional group Chemical group 0.000 abstract 2
125000001072 heteroaryl group Chemical group 0.000 abstract 2
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
125000004043 oxo group Chemical group O=* 0.000 abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
206010047700 Vomiting Diseases 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 abstract 1
125000002541 furyl group Chemical group 0.000 abstract 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
125000001624 naphthyl group Chemical group 0.000 abstract 1
125000004076 pyridyl group Chemical group 0.000 abstract 1
125000005493 quinolyl group Chemical group 0.000 abstract 1
125000003831 tetrazolyl group Chemical group 0.000 abstract 1
125000000335 thiazolyl group Chemical group 0.000 abstract 1
125000001544 thienyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Hematology (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Cardiology (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

AT95907110T 1994-02-11 1995-02-06 Aralkoxy und aralkylthio substituierte azacyclische verbindungen als tachykinin antagonisten ATE192737T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB9402688A GB9402688D0 (en)	1994-02-11	1994-02-11	Therapeutic agents
PCT/GB1995/000228 WO1995021819A1 (en)	1994-02-11	1995-02-06	Aralkoxy and aralkylthio substituted azacyclic compounds as tachykinin antagonists

Publications (1)

Publication Number	Publication Date
ATE192737T1 true ATE192737T1 (de)	2000-05-15

Family

ID=10750268

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95907110T ATE192737T1 (de)	1994-02-11	1995-02-06	Aralkoxy und aralkylthio substituierte azacyclische verbindungen als tachykinin antagonisten

Country Status (10)

Country	Link
US (1)	US5665883A (de)
EP (1)	EP0743939B1 (de)
JP (1)	JPH09508901A (de)
AT (1)	ATE192737T1 (de)
AU (1)	AU685582B2 (de)
CA (1)	CA2182734A1 (de)
DE (1)	DE69516853T2 (de)
ES (1)	ES2147603T3 (de)
GB (1)	GB9402688D0 (de)
WO (1)	WO1995021819A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5780487A (en) *	1995-08-07	1998-07-14	Amer Moh Samir	S-2'- 2-(1-methyl-2-piperidyl) ethyl! cinnamanilide
DE19938736A1 (de)	1999-08-16	2001-02-22	Bayer Ag	Verfahren zur Herstellung von [Bis-(trifluormethyl)-phenyl]-essigsäuren und deren Alkylestern sowie [Bis-(trifluormethyl)-phenyl]-malonsäure-dialkylester
US7163949B1 (en)	1999-11-03	2007-01-16	Amr Technology, Inc.	4-phenyl substituted tetrahydroisoquinolines and use thereof
MXPA02004330A (es)	1999-11-03	2004-07-30	Albany Molecular Res Inc	Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
CA2412355A1 (en) *	2000-06-12	2001-12-20	University Of Rochester	Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
KR100821410B1 (ko)	2000-07-11	2008-04-10	에이엠알 테크놀로지, 인크.	4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도
WO2003049698A2 (en) *	2001-12-10	2003-06-19	Temple University - Of The Commonwealth System Of Higher Education	Substituted hydrazones as inhibitors of cyclooxygenase-2
US20060205724A1 (en) *	2002-05-29	2006-09-14	The Regents Of The University Of California	Antagonizing nk-1 receptors inhibits consumption of substances of abuse
JP2004285038A (ja) *	2002-05-31	2004-10-14	Takeda Chem Ind Ltd	ピペリジン誘導体、その製造法および用途
NZ552397A (en)	2004-07-15	2011-04-29	Amr Technology Inc	Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ES2382814T3 (es)	2005-05-17	2012-06-13	Merck Sharp & Dohme Ltd.	Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
KR101594898B1 (ko)	2005-07-15	2016-02-18	알바니 몰레큘라 리써치, 인크.	아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
EP1940842B1 (de)	2005-09-29	2012-05-30	Merck Sharp & Dohme Corp.	Acylierte spiropiperidinderivate als modulatoren des melanocortin-4-rezeptors
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
US8173629B2 (en)	2006-09-22	2012-05-08	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (ja)	2007-01-10	2011-01-12	イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー	ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
JP5319518B2 (ja)	2007-04-02	2013-10-16	Ｍｓｄ株式会社	インドールジオン誘導体
AU2008269154B2 (en)	2007-06-27	2014-06-12	Merck Sharp & Dohme Llc	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AU2009222122A1 (en)	2008-03-03	2009-09-11	Tiger Pharmatech	Tyrosine kinase inhibitors
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en)	2009-04-01	2010-10-07	Merck Sharp & Dohme Corp.	Inhibitors of akt activity
AU2010247735B2 (en)	2009-05-12	2015-07-16	Albany Molecular Research, Inc.	Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
AU2010247763B2 (en)	2009-05-12	2015-12-24	Albany Molecular Research, Inc.	7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
WO2010132437A1 (en)	2009-05-12	2010-11-18	Albany Molecular Research, Inc.	Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
PE20121172A1 (es)	2009-10-14	2012-09-05	Merck Sharp & Dohme	Piperidinas sustituidas con actividad en la hdm2
WO2011163330A1 (en)	2010-06-24	2011-12-29	Merck Sharp & Dohme Corp.	Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (de)	2010-08-02	2018-06-06	Sirna Therapeutics, Inc.	Durch rna-interferenz vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina)
US9029341B2 (en)	2010-08-17	2015-05-12	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US8883801B2 (en)	2010-08-23	2014-11-11	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012026914A1 (en) *	2010-08-23	2012-03-01	Sam Amer & Co., Inc.	Methods and compositions for treating internal and external hemorrhoids
EP2613782B1 (de)	2010-09-01	2016-11-02	Merck Sharp & Dohme Corp.	Indazolderivate als erk-hemmer
US9242981B2 (en)	2010-09-16	2016-01-26	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en)	2010-12-21	2012-06-28	Schering Corporation	Indazole derivatives useful as erk inhibitors
AU2012245971A1 (en)	2011-04-21	2013-10-17	Piramal Enterprises Limited	A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (de)	2011-10-27	2018-04-04	Merck Sharp & Dohme Corp.	Neue verbindungen als erk-hemmer
US20150299696A1 (en)	2012-05-02	2015-10-22	Sirna Therapeutics, Inc.	SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
RU2660429C2 (ru)	2012-09-28	2018-07-06	Мерк Шарп И Доум Корп.	Новые соединения, которые являются ингибиторами erk
RS56680B1 (sr)	2012-11-28	2018-03-30	Merck Sharp & Dohme	Kompozicije i postupci za lečenje kancera
KR102196882B1 (ko)	2012-12-20	2020-12-30	머크 샤프 앤드 돔 코포레이션	Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014120748A1 (en)	2013-01-30	2014-08-07	Merck Sharp & Dohme Corp.	2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Circular polynucleotides
EP3525785B1 (de)	2016-10-12	2025-08-27	Merck Sharp & Dohme LLC	Kdm5-inhibitoren
EP3706747B1 (de)	2017-11-08	2025-09-03	Merck Sharp & Dohme LLC	Prmt5-inhibitoren
US10947234B2 (en)	2017-11-08	2021-03-16	Merck Sharp & Dohme Corp.	PRMT5 inhibitors
US11981701B2 (en)	2018-08-07	2024-05-14	Merck Sharp & Dohme Llc	PRMT5 inhibitors
US12173026B2 (en)	2018-08-07	2024-12-24	Merck Sharp & Dohme Llc	PRMT5 inhibitors
EP3833668B1 (de)	2018-08-07	2025-03-19	Merck Sharp & Dohme LLC	Prmt5-inhibitoren

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0600952B1 (de) *	1991-08-20	1996-04-17	MERCK SHARP & DOHME LTD.	Azacyclische verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ES2124318T3 (es) *	1992-07-28	1999-02-01	Merck Sharp & Dohme	Compuestos azaciclicos.
ATE166867T1 (de) *	1993-02-18	1998-06-15	Merck Sharp & Dohme	Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagoniste

1994
- 1994-02-11 GB GB9402688A patent/GB9402688D0/en active Pending
1995
- 1995-02-06 US US08/676,157 patent/US5665883A/en not_active Expired - Fee Related
- 1995-02-06 AU AU15440/95A patent/AU685582B2/en not_active Ceased
- 1995-02-06 EP EP95907110A patent/EP0743939B1/de not_active Expired - Lifetime
- 1995-02-06 JP JP7521038A patent/JPH09508901A/ja active Pending
- 1995-02-06 AT AT95907110T patent/ATE192737T1/de not_active IP Right Cessation
- 1995-02-06 WO PCT/GB1995/000228 patent/WO1995021819A1/en not_active Ceased
- 1995-02-06 CA CA002182734A patent/CA2182734A1/en not_active Abandoned
- 1995-02-06 ES ES95907110T patent/ES2147603T3/es not_active Expired - Lifetime
- 1995-02-06 DE DE69516853T patent/DE69516853T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO1995021819A1 (en)	1995-08-17
US5665883A (en)	1997-09-09
CA2182734A1 (en)	1995-08-17
DE69516853D1 (de)	2000-06-15
AU1544095A (en)	1995-08-29
AU685582B2 (en)	1998-01-22
ES2147603T3 (es)	2000-09-16
EP0743939B1 (de)	2000-05-10
DE69516853T2 (de)	2000-11-16
GB9402688D0 (en)	1994-04-06
EP0743939A1 (de)	1996-11-27
JPH09508901A (ja)	1997-09-09

Legal Events

Date	Code	Title	Description
2000-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE192737T1 (de)	2000-05-15	Aralkoxy und aralkylthio substituierte azacyclische verbindungen als tachykinin antagonisten
ATE166867T1 (de)	1998-06-15	Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagoniste
ATE378043T1 (de)	2007-11-15	Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha- synuclein fibril krankheiten
DE69504300D1 (de)	1998-10-01	Gem-bissubstituierte azazyclische tachykinin-antagonisten
DE69208089D1 (de)	1996-03-14	Aromatische verbindungen diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische verwendung
SE0104332D0 (sv)	2001-12-19	Therapeutic agents
ZA987087B (en)	1999-02-08	Chemical compounds
BRPI0412219A (pt)	2006-08-22	composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para regular a transdução de sinal método para tratamento ou prevenção de uma doença
ATE490244T1 (de)	2010-12-15	Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
DE69628853D1 (de)	2003-07-31	Tri-substituierte phenyl-derivative verwendbar als pde iv inhibitoren
DE69224196D1 (de)	1998-02-26	3-aminopiperidine derivate und verwandete stickstoff enthaltende heterocyclische verbindungen
NO20071719L (no)	2007-05-31	Pyridylinhibitorer for "hedgehog"-signalisering
MXPA02011417A (es)	2003-04-25	1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos.
ATE427308T1 (de)	2009-04-15	Neue heterozyklische verbindungen, die sich fur die behandlung von entzundlichen und allergischen erkrankungen eignen: verfahren zu deren herstellung und pharmazeutische zusammensetzungen,die diese enthalten
RU2005104434A (ru)	2005-07-20	Производные 1-гетероциклилалкил-3-сульфонилиндола или - индазола как лиганды 5-гидрокситриптамина-6
NO992770L (no)	1999-06-08	Nye heterocyklisk substituerte benzamider og deres anvendelse ved bekjempelse av sykdommer
MXPA02011418A (es)	2003-04-25	1-aminoalquil-lactamas sustituidas y su uso como antagonistas del receptor muscarinico.
ES2113081T3 (es)	1998-04-16	1,4-benzotiazepinas utiles como agentes neurologicos.
RU2005128556A (ru)	2006-01-27	Гетероциклил-3-сульфонилиндазолы в качестве лигандов 5-гидрокситриптамина-6
NO20060446L (no)	2006-03-27	Trisykliske delta-opioidmodulatorer
GB9305641D0 (en)	1993-05-05	Therapeutic agents
DE3861926D1 (de)	1991-04-11	Polyzyklische aromatische verbindungen, verfahren zu deren herstellung, deren verwendung in menschlicher und tierischer medizin und in der kosmetik.
ATE248809T1 (de)	2003-09-15	Gegen picorna-viren gerichtete verbindungen, zusammensetzungen die diese verbindungen enthalten und methoden zu ihrer anwendung
DE602005021698D1 (de)	2010-07-15	Sauerstoffhaltige heterocyclen als glycintransporterinhibierende verbindungen
PL316964A1 (en)	1997-03-03	O-acyl 4-phenyl cyclohexanol, yheir salts, therapeutic agents containing such compound as well as their application and method of obtaining them